India Exchange Filings

Biocon Pebrilzo U.S. FDA Approval Press Release

Biocon Ltd receives U.S. FDA approval for Pebrilzo, a Perjeta biosimilar for HER2-positive breast cancer

  • Approved for specified treatment regimens in HER2-positive metastatic and early breast cancer.
  • Biocon’s oncology portfolio now includes five U.S.-approved cancer biosimilars.
  • Under a settlement and licence agreement with Genentech, the earliest U.S. launch is expected in Q3 2028.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.